Home > Neurology > EAN 2020 > Multiple Sclerosis > Long-term safety of satralizumab consistent with double-blind periods

Long-term safety of satralizumab consistent with double-blind periods

In patients with neuromyelitis optica spectrum disorder (NMOSD), satralizumab continued to be well tolerated and to have a favourable safety profile when open-label extension period data were included in the analysis [1]. The overall satralizumab treatment data were consistent with the double-blind periods.

Satralizumab is a humanised monoclonal antibody that binds to and blocks the IL-6 receptor and was shown to reduce NMOSD relapse risk in both the SAkuraSky (satralizumab in combination with baseline immunosuppressants), and the SAkuraStar (satralizumab monotherapy) phase 3 trials. The pooled double-blind population included 178 patients (satralizumab, n=104; placebo, n=74); 166 patients received satralizumab in the open-label extension period. The combined double-blind/extension period was defined as the overall satralizumab treatment period, in wh...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on